Trial Profile
A Prospective Open-label Dose Escalation Phase 1 Study to Investigate the Safety and Tolerability, and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose, of HLX10 in Patients With Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Jul 2022
Price :
$35
*
At a glance
- Drugs Serplulimab (Primary)
- Indications Carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors Henlix Biotech
- 07 Jun 2022 Results (n=29; as of 27 Jul 2020) reporting data from dose-finding cohort presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 10 May 2019 Planned End Date changed from 1 Jan 2020 to 31 Aug 2020.
- 10 May 2019 Planned primary completion date changed from 1 Jul 2019 to 30 Jun 2020.